Copyright
©The Author(s) 2022.
World J Gastrointest Oncol. Sep 15, 2022; 14(9): 1637-1653
Published online Sep 15, 2022. doi: 10.4251/wjgo.v14.i9.1637
Published online Sep 15, 2022. doi: 10.4251/wjgo.v14.i9.1637
Cell/cancer type | Findings | Research method | Ref. | |
1 | Colorectal cancer | L-CaD was expressed in colorectal cancer and liver metastasis, compared with normal tissue. L-CaD was associated with a poor response to chemotherapy. L-CaD was associated with resistance to 5-Fu treatment and caused an increase in p21 and cleaved-PARP and a decrease in the expression of NF-κB and p-mTOR in vitro | Clinical, functional | Kim et al[39], 2012 |
2 | Colon, bladder, and prostate | CALD1 may indicate cancer-related splicing events. CALD1 was identified as a tumor-specific splicing variant in colon and urinary bladder cancer tissue samples | Bioinformatics, and experimental | Thorsen et al[40], 2008 |
3 | Colorectal cancer | CALD1 was upregulated and associated with M2 macrophage infiltration, angiogenesis, and TGF-β in stage III/IV mismatch-proficient colorectal cancer. High expression of CALD1 was significantly correlated with transendothelial migration. Cancer cell proliferation, invasion, and migration abilities were suppressed after reducing CALD1 expression in vitro | Clinical, bioinformatics, functional | Zheng et al[41], 2021 |
4 | Colorectal cancer-early-onset | CALD overexpressed in early-onset colorectal cancer | Bioinformatics, in silico, clinical | Zhao et al[42], 2019 |
5 | Rectal cancer | CALD1 overexpressed in nonresponders to chemotherapy | Clinical | Chauvin et al[43], 2018 |
6 | Colorectal cancer | Novel l-CaD isoforms produced by alternative splicing of CALD1 played a role in colorectal cancer metastasis | Bioinformatics, in silico | Lian et al[44], 2020 |
7 | Gastric cancer | CALD1 is a novel target of TEA domain family member 4 that is involved in cell proliferation and migration | Bioinformatics, in silico | Lim et al[45], 2014 |
8 | Gastric cancer | High expression of CALD1 is associated with poor overall survival and with immune infiltration in gastric cancer | Bioinformatics, in silico | Liu et al[46], 2021 |
9 | Breast cancer, study of ER | Silencing of ER in MCF7 cells upregulated CALD1, concomitantly with the acquisition of a new phenotype that encompasses increased growth rates, loss of cell-to-cell adhesion and a redistribution of the cytoskeletal components, resulting in increased motility | Functional analysis, basic study | Al Saleh et al[47], 2011 |
10 | Breast cancer-ER-positive | ANXA1 and CALD1 were associated with downregulation of ER via activation of NF-κB signaling, which blocks apoptosis and allows cancer cells to become independent of estrogen. ANXA1 and CALD1 proteins are independent markers for tamoxifen therapy outcome (resistance) and are associated with fast tumor progression | Clinical, association, pathway analysis | De Marchi et al[48], 2016 |
11 | Normal mouse mammary cells | The expression level and phosphorylation state of CaD increase as a function of time after induction of EMT by TGF-β1, and these changes in CaD correlate with increased focal adhesion number and size and increased cell contractility | Functional analysis, basic study | Nalluri et al[49], 2018 |
12 | Bladder cancer | L-CaD overexpression in primary nonmuscle invasive bladder cancer is significantly associated with tumor progression. L-CaD is implicated in increased cell motility and invasive characteristics through morphological changes in bladder cancer cells | Clinical, functional | Lee et al[50], 2015 |
13 | Bladder cancer | CaD was identified as one of the proteins with significant differential expression between bladder cancer tissue and normal urothelial tissue, using antibody microarray profiling of tissue samples | Clinical | Lee et al[51], 2015 |
14 | Bladder cancer | Low CALD1 in tumor is associated with a good prognosis | Bioinformatics, in silico | Liu et al[52], 2019 |
15 | Bladder cancer | CALD1 was correlated with aggressive features and poor overall survival. CALD1 promotes tumor cell growth, migration, invasion, and the cell cycle; it inhibits tumor cell apoptosis in vitro and in vivo. CALD1 expression was positively correlated with JAK/STAT activation resulting in PD-L1 overexpression | Clinical, functional | Li et al[53], 2021 |
16 | Bladder cancer | CALD1 was overexpressed in CAFs, as well as macrophages and T cells in the microenvironment of bladder tumors and was associated with oncogenic features | Bioinformatics, functional | Du et al[54], 2021 |
17 | Bladder cancer | MIR100HG inhibits the expression of miR-142-5p, resulting in the upregulation of CALD1 and acquisition of aggressive features in bladder cancer | Clinical, bioinformatics, functional | Zhang et al[55], 2021 |
18 | Lung cancer | CaD is overexpressed in brain metastases of lung cancer | Clinical, expression | Zhang et al[56], 2014 |
19 | NSCLC | Activation of the anaphase-promoting complex by p53 induces a state of dormancy in NSCLC cells after 5-Fu. Subsequently, EMT and CaD upregulation were associated with dormant cancer stem cells | Experimental, functional | Dai et al[57], 2016 |
20 | Squamous cell carcinoma of oral cavity | CaD expression is associated with a poor prognosis in patients with oral squamous cell carcinoma. CaD increased invasion and migration and was elevated in patients’ serum | Clinical, functional | Chang et al[58], 2013 |
21 | Nasopharyngeal carcinoma | Bone marrow-derived mesenchymal stem cells secreted nitric oxide in the nasopharyngeal carcinoma tumor environment, which resulted in translocation of CaD to the podosome in a Ca2+/calmodulin manner in tumor cells and promotion of their invasion and metastatic ability | Functional | Zhang et al[59], 2014 |
22 | Glioma | CALD1 was upregulated in neoplastic cells. CALD1 was associated with a progressive vessel architecture. CALD1 may serve as marker of glioma progression | Clinical, functional | Cheng et al[60], 2021 |
23 | Glioma, patients’ serum | The serum level of l-CaD was significantly higher in the group of glioma patients as compared to any of the other brain tumor groups | Clinical | Zheng et al[61], 2005 |
24 | Glioma-associated blood vessels | Splicing variants of CALD1 are differentially expressed in glioma neovascularization versus normal brain microvasculature. The mis-splicing of CALD1 correlated with the breakdown of tight junctions among vascular endothelial cells | Expression, functional | Zheng et al[62], 2004 |
25 | Endothelial cells | L-CaD is involved in the migration of endothelial cells and/or endothelial progenitor cells into human neoplasms (gliomas, breast cancers, renal cell carcinomas) where they contribute to tumor angiogenesis | Expression, functional | Zheng et al[63], 2007 |
26 | Kidney epithelial cells, mouse mammary cells | CaD is activated and upregulated upon TGF-β induction of EMT. CALD1 overexpression is a key component in TGF-β-driven EMT | Functional | Morita et al[64], 2007 |
27 | Not specified | CaD maintains newly polymerized actin in a distinct state that has a higher affinity for the Arp2/3 complex | Functional | Jensen et al[65], 2012 |
Cell/cancer type | Findings | Research method | Ref. | |
1 | Colorectal cancer | An alternatively spliced form of CALD1 was decreased in tissues from colorectal tumor as compared to adjacent normal tissues | Bioinformatics, in silico | Liu et al[66], 2018 |
2 | Gastric cancer | CaD is decreased in metastasis-derived gastric cancer cell lines. Knockdown of CaD resulted in an increase in cell migration and invasion | Proteomics, clinical, functional | Hou et al[67], 2013 |
3 | Breast, colorectal, and thyroid cancer cells | The ectopic expression of l-CaD reduced the number of podosomes/invadopodia and suppressed cell invasion | Basic, functional | Yoshio et al[68], 2007 |
4 | Breast cancer, and rat aorta cell lines | PKGI-β enhances breast cancer cell motility and invasive capacity by phosphorylating CaD. Knockdown of endogenous CaD in MDA-MB-231 breast cancer cells had pro-migratory and pro-invasive effects | Basic, functional | Schwappacher et al[69], 2013 |
5 | Prostate cancer | Leupaxin phosphorylates CaD leading to its downregulation, and this downregulation of CaD increased migration and invasion of prostate cancer cells | Basic experimental | Dierks et al[70], 2015 |
6 | Vascular smooth muscle cells and NIH 3T3 fibroblast cells | CaD upregulation mediates p53 suppression of Src-induced podosome and rosette formation and cellular invasiveness. The study is based on normal cells and whether or not it applies to malignancy remains to be clarified | Basic, functional | Mukhopadhyay et al[71], 2009 |
- Citation: Alnuaimi AR, Nair VA, Malhab LJB, Abu-Gharbieh E, Ranade AV, Pintus G, Hamad M, Busch H, Kirfel J, Hamoudi R, Abdel-Rahman WM. Emerging role of caldesmon in cancer: A potential biomarker for colorectal cancer and other cancers. World J Gastrointest Oncol 2022; 14(9): 1637-1653
- URL: https://www.wjgnet.com/1948-5204/full/v14/i9/1637.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v14.i9.1637